X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Abcuro will use the proceeds from the financing to complete a Phase 2/3 registrational clinical trial evaluating ABC008, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM).
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 17, 2023
Details:
ABC008 is a first-in-class anti-KLRG1 antibody, designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and mature T cell malignancies.
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.
Lead Product(s): ABC008
Therapeutic Area: Oncology Product Name: ABC008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Preliminary data also show potential improvement in disease severity of IBM in the first cohort and evidence of a dose response in the second cohort with ABC008 0.5 mg/kg for depletion of highly cytotoxic T cells.
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
ABC008 is an anti-KLRG1 antibody capable of selectively depleting subpopulations of highly cytotoxic, tissue-damaging, late-differentiated effector memory (TEM) and effector (TEMRA) T cells for treatment of inclusion body myositis (IBM), an autoimmune disease.
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mass General Brigham Ventures
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
